![Sarah Bridges](https://profiles-cardiff.imgix.net/attachments/638?w=200&h=200&auto=format&crop=faces&fit=crop&q=90")
Mrs Sarah Bridges
Trial Manager
- BridgesSE@cardiff.ac.uk
- Neuadd Meirionnydd, Room 6th Floor, University Hospital of Wales, Heath Park, Cardiff, CF14 4YS
Overview
I am the Trial Manager for the SCOPE2 trial, a multi-centre randomised Phase II/III study of radiotherapy dose escalation in patients with oesophageal cancer treated with definitive chemoradiotherapy (with an embedded Phase II study of an additional PET scan informing chemotherapy regimen in patients with poor early response). SCOPE2 is currently open and recruiting.
I also manage the FOLFERA trial, a closed randomised Phase II study of the addition of an endothelin receptor antagonist to the FOLFIRI chemotherapy regimen in patients with metastatic colorectal cancer after failure of an oxaliplatin-containing regimen.
In the autumn of 2020 I was Trial Manager for the Novavax Covid-19 vaccine study at its facility in North Wales in collaboration with Public Health Wales, Health and Care Research Wales, and Betsi Cadwaladr University Health Board. I am also involved in the development of a brain cancer study alongside colleagues in Imperial, and am the co-Principal Investigator of Talking Trials, a Wellcome Trust Public Engagement Proof of Concept project exploring perceptions of clinical trials amongst those from minority ethnic backgrounds living in Riverside, Cardiff.
Publication
2023
- Mukherjee, S. et al. 2023. Efficacy of early PET-CT directed switch to carboplatin and paclitaxel based definitive chemoradiotherapy in patients with oesophageal cancer who have a poor early response to induction cisplatin and capecitabine in the UK: a multi-centre randomised controlled phase II trial. EClinicalMedicine 61, article number: 102059. (10.1016/j.eclinm.2023.102059)
- Bridges, S. et al. 2023. Talking Trials: An arts‐based exploration of attitudes to clinical trials amongst minority ethnic members of the South Riverside Community of Cardiff. Health Expectations 26(3), pp. 1236-1245. (10.1111/hex.13740)
2022
- Bridges, S. et al. 2022. SCOPE 2 – Still answering the unanswered questions in oesophageal radiotherapy? SCOPE 2: a Randomised phase II/III trial to study radiotherapy dose escalation in patients with oesophageal cancer treated with definitive chemoradiation with an embedded phase II trial for patients with a poor early response using positron emission tomography/computed tomography. Clinical Oncology 34(7), pp. E269-E280. (10.1016/j.clon.2022.03.019)
2015
- Hurt, C. N. et al. 2015. Health-related quality of life in SCALOP, a randomized Phase 2 trial comparing chemoradiation therapy regimens in locally advanced pancreatic cancer. International Journal of Radiation Oncology Biology Physics 93(4), pp. 810-818.
2013
- Nixon, L. S. et al. 2013. The SCALOP Trial Plan Assessment Form (PAF) as a tool for Radiation Therapy Trials Quality Assurance (RTTQA). International Journal of Radiation Oncology*Biology*Physics 87(2), pp. S306. (10.1016/j.ijrobp.2013.06.804)
2010
- Mukherjee, S. et al. 2010. A Cancer Research UK multicenter randomized phase II study of induction chemotherapy followed by gemcitabine- or capecitabine-based chemoradiotherapy for locally advanced nonmetastatic pancreatic cancer. American Journal of Clinical Oncology 28
Articles
- Mukherjee, S. et al. 2023. Efficacy of early PET-CT directed switch to carboplatin and paclitaxel based definitive chemoradiotherapy in patients with oesophageal cancer who have a poor early response to induction cisplatin and capecitabine in the UK: a multi-centre randomised controlled phase II trial. EClinicalMedicine 61, article number: 102059. (10.1016/j.eclinm.2023.102059)
- Bridges, S. et al. 2023. Talking Trials: An arts‐based exploration of attitudes to clinical trials amongst minority ethnic members of the South Riverside Community of Cardiff. Health Expectations 26(3), pp. 1236-1245. (10.1111/hex.13740)
- Bridges, S. et al. 2022. SCOPE 2 – Still answering the unanswered questions in oesophageal radiotherapy? SCOPE 2: a Randomised phase II/III trial to study radiotherapy dose escalation in patients with oesophageal cancer treated with definitive chemoradiation with an embedded phase II trial for patients with a poor early response using positron emission tomography/computed tomography. Clinical Oncology 34(7), pp. E269-E280. (10.1016/j.clon.2022.03.019)
- Hurt, C. N. et al. 2015. Health-related quality of life in SCALOP, a randomized Phase 2 trial comparing chemoradiation therapy regimens in locally advanced pancreatic cancer. International Journal of Radiation Oncology Biology Physics 93(4), pp. 810-818.
- Nixon, L. S. et al. 2013. The SCALOP Trial Plan Assessment Form (PAF) as a tool for Radiation Therapy Trials Quality Assurance (RTTQA). International Journal of Radiation Oncology*Biology*Physics 87(2), pp. S306. (10.1016/j.ijrobp.2013.06.804)
- Mukherjee, S. et al. 2010. A Cancer Research UK multicenter randomized phase II study of induction chemotherapy followed by gemcitabine- or capecitabine-based chemoradiotherapy for locally advanced nonmetastatic pancreatic cancer. American Journal of Clinical Oncology 28
- Nixon, L. S. et al. 2013. The SCALOP Trial Plan Assessment Form (PAF) as a tool for Radiation Therapy Trials Quality Assurance (RTTQA). International Journal of Radiation Oncology*Biology*Physics 87(2), pp. S306. (10.1016/j.ijrobp.2013.06.804)
- Mukherjee, S. et al. 2010. A Cancer Research UK multicenter randomized phase II study of induction chemotherapy followed by gemcitabine- or capecitabine-based chemoradiotherapy for locally advanced nonmetastatic pancreatic cancer. American Journal of Clinical Oncology 28